• Record: found
  • Abstract: found
  • Article: not found

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Science (New York, N.Y.)

Animals, Antineoplastic Agents, pharmacology, therapeutic use, CHO Cells, Carcinoma, Non-Small-Cell Lung, drug therapy, genetics, metabolism, pathology, Cell Line, Tumor, Cell Proliferation, drug effects, Cricetinae, Cricetulus, Drug Resistance, Neoplasm, Enzyme Inhibitors, Gene Amplification, Humans, Indoles, Lung Neoplasms, Phosphatidylinositol 3-Kinases, Phosphorylation, Proto-Oncogene Proteins, Proto-Oncogene Proteins c-akt, Proto-Oncogene Proteins c-met, Quinazolines, Receptor, ErbB-3, Receptors, Growth Factor, Signal Transduction, Sulfones

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib. We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.

      Related collections

      Author and article information



      Comment on this article